The prevalence of the IGSF-1 mutation in children who develop central hypothyroidism after starting Growth Hormone treatment.

Withdrawn

• Conditions: hypothyroidism; too little thyroid hormones; 10021112

• Registration Number: NL-OMON38491
• Lead Sponsor: Academisch Medisch Centrum

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 29 April 2024

Recruitment & Eligibility

• Status: Withdrawn
• Sex: Not specified
• Target Recruitment: 27

Inclusion Criteria

Children receiving thyroxine within two years after starting growth hormone treatment.

Exclusion Criteria

Children with isolated Growth Hormone deficiency ( not using thyroxine ) or children already known with Multiple Pituitary Hormone deficiency at the moment of starting growth hormone treatment.

Study & Design

• Study Type: Observational invasive
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>- To gather the exact medical data of the 27 children who are being treated<br /><br>with thyroxine, to confirm that they were diagnosed with central<br /><br>hypothyroidism. (based on the concentrations of FT4 and TSH before starting<br /><br>with GH)<br /><br>- To evaluate growth velocity and compare this with children diagnosed with<br /><br>isolated growth hormone deficiency.<br /><br>- To determine the prevalence of the occurrence of the IGSF-1 mutation in<br /><br>children which develop a central hypothyroidism after start of GH.</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>N.V.T.</p><br>